• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

byArnav Agarwal, MD
December 17, 2019
in Gastroenterology, Infectious Disease, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

Antibody testing may provide diagnostic support for SARS-CoV-2 infection

#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

1. Enterotoxigenic Escherichia coli vaccination may provide significant immunogenic benefits in young children and infants in low- and middle-income countries with minimal associated toxicity.

Evidence Rating Level: 1 (Excellent)

Enterotoxigenic Escherichia coli (E. coli) is associated with diarrhea, stunting and significant morbidity and mortality in children, particularly from low-income and middle-income countries. A University of Gothenburg team has developed an enterotoxigenic E. coli vaccine (ETVAX) with strains of recombinant E. coli overexpressing the most prevalent colonization factors at higher concentrations. ETVAX was proven to be safe, provided significant fecal secretory IgA, and IgA antibody lymphocyte secretory responses across all colonization factors, along with immunologic memory when tested in Swedish adults. Its immunogenicity and safety were also proven in Bangladeshi adults. This large-scale, dose-escalation, age-descending phase 1/2 Bangladesh-based trial aimed to evaluate the safety and immunogenicity of ETVAX in children, with the primary objective of establishing the largest tolerated dose of ETVAX and the potential of the vaccine to induce mucosal and systemic immune responses against five primary antigens. Healthy children aged 6 to 59 months were deemed eligible and were randomly assigned using block randomization to receive ETVAX with or without a double-mutant heat-labile enterotoxin, or placebo. Two doses were administered two weeks apart across arms. The primary endpoint was safety and tolerability in children receiving at least one vaccine dose, with antibody response to vaccine antigens, defined as a minimum of a two-fold increase in antibody levels from baseline, was evaluated as a secondary endpoint. Overall, 430 children were enrolled and randomly assigned between December 2015 and January 2017, and all participants received at least one vaccine dose. The most common adverse event reported was emesis (52/430 participants; 12.1%). Only three serious adverse events occurred and were considered unrelated to the intervention. Most adverse events were reported as mild. While antibody responses were less frequent and of lower magnitude among younger children aged 6 to 11 months, most participants aged 12 to 23 months and 24 to 59 months had detectable IgA antibody responses against all five primary vaccine antigens. Fifty-six percent of infants aged 6 to 11 months who received treatment developed mucosal responses to at least three vaccine antigens, compared to 29% of infants receiving placebo. Study findings suggest that infants and children may develop significant immune responses with administration of ETVAX with minimal serious toxicity, which may further be enhanced by co-administration of a double-mutant heat-labile enterotoxin.

Click to read the study in Lancet Infectious Diseases

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BangladeshenterotoxinEscherichia coliETVAXIgA
Previous Post

Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence

Next Post

#VisualAbstract: Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest

RelatedReports

Caplacizumab may induce faster resolution of a thrombotic thrombocytopenic purpura episode
Nephrology

Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

May 18, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Infectious Disease

Antibody testing may provide diagnostic support for SARS-CoV-2 infection

July 15, 2020
#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants
StudyGraphics

#VisualAbstract: Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants

January 4, 2020
Publication of pneumonia antibiotic guidelines changed prescribing trends
Infectious Disease

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

December 18, 2019
Next Post
#VisualAbstract: Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest

#VisualAbstract: Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest

Publication of pneumonia antibiotic guidelines changed prescribing trends

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community

Pre-operative magnetic resonance imaging may not improve contralateral breast cancer detection

Low risk of nephrogenic systemic fibrosis with group II gadolinium contrast agents in chronic kidney disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Subthreshold micropulse laser is equivalent to standard laser for treating diabetic macular edema
  • Gadolinium-containing contrast associated with nephrogenic fibrosing dermopathy and systemic fibrosis [Classics Series]
  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.